LB PHARMACEUTICALS INC (LBRX) Stock Profile — Insider Trades & Financials

Net Income-$11.5M

EPS$-6.26

Market Cap$744.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Heather Turner

CEO & Executive Director

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Founded: 2015
Employees: 16
Headquarters: New York, New York, United States
Website

⚡

Core Efficiency

ROE?

-3.81%

ROA?

-3.67%

D/E Ratio?

0.04

📊

Profitability Ratios

Current Ratio?

41.44

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 22, 2026 (in 135 days)

Annual Report (10-K) — Estimated

Aug 22, 2026

Predicted10-K

Mar 26, 2026

10-KQ4 20253d after period end

Nov 6, 2025

10-QQ3 20250d after period end

Loading company sections...

LB PHARMACEUTICALS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness